## Phase 2 Clinical Trial Summary

- **Participants**: 120 adults aged 65â€“85
- **Duration**: 12 months
- **Endpoints**: Reduction in systemic inflammation markers, telomere length stabilization, improved mitochondrial function
- **Results**: 78% showed measurable improvement in inflammatory biomarkers; 42% reported enhanced cognitive clarity
